RecruitingNot ApplicableNCT06789406
PMCF Study of the Axonics SNM System Model 5101 (R20)
Post-Market Clinical Follow-up Study of the Axonics SNM System Model 5101 (R20)
Sponsor
Axonics, Inc.
Enrollment
55 participants
Start Date
Sep 18, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Post-market clinical follow-up for continued assessment of safety and performance to confirm long-term outcomes of the Axonics SNM System INS Model 5101.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- years or older
- Primary indication of OAB (urinary urgency incontinence (UUI) / urinary frequency (UF) who are not candidates for, or who have failed conservative treatment
- Willing and capable to provide written consent and agrees to comply with specified evaluations at clinical centers for all follow-up assessments
Exclusion Criteria6
- Any significant medical condition that is likely to interfere with procedures, device operation, or likely to confound evaluation of endpoints (i.e., neurological conditions such as multiple sclerosis)
- Any psychiatric or personality disorder that is likely to interfere with procedures at the discretion of the participating physician; this may include poor understanding or compliance with requirements
- Previously underwent an external sacral neuromodulation SNM trial and was deemed a non-responder or was previously implanted with a sacral neuromodulation device and did not get therapeutic benefit (a non-responder)
- History of allergic response to titanium, zirconia, polyurethane, epoxy, or silicone
- A female who is breastfeeding
- A female with a positive urine pregnancy test
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICEAxonics SNM System INS Model 5101 (R20)
Participants treated with the rechargeable Axonics SNM System Model 5101 also referred to as R20. Commercial devices used in this study are within their intended use as described in each geography's approved instructions for use.
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06789406
Related Trials
Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women
NCT074733101 location
Zinc Supplementation With Botulinum Toxin for Overactive Bladder
NCT074055541 location
Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study
NCT0741696814 locations
INOPASE - Performance and Safety Study of a Personalised SNM System
NCT071934072 locations
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
NCT0719565615 locations